The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Rifampin drastically reduces plasma concentrations and effects of oral midazolam
Abstract
BACKGROUND: Midazolam is a short-acting benzodiazepine that is metabolized by CYP3A enzymes. Rifampin is a potent enzyme inducer that may seriously interact with some substrates of CYP3A4. METHODS: The possible interaction between rifampin and midazolam was investigated in a double-blind, randomized crossover study of two phases. Rifampin (600 mg once daily) or placebo was administered to 10 healthy subjects for 5 days. On the sixth day, the subjects were given 15 mg oral midazolam. Plasma samples were collected for determination of midazolam, and pharmacodynamic effects were measured for 10 hours. RESULTS: Rifampin pretreatment decreased the area under the plasma midazolam concentration-time curve by 96% (i.e., from 10.2 +/- 0.8 to 0.42 +/- 0.05 micrograms.min/ml [mean +/- SEM; p < 0.001]) and the maximum concentration by 94% (i.e., from 55 +/- 4 to 3.5 +/- 0.7 ng/ml [p < 0.001]). The elimination half-life of midazolam was decreased from 3.1 +/- 0.2 to 1.3 +/- 0.2 hours by rifampin (p < 0.001). During the rifampin phase, the pharmacodynamic effects of midazolam were markedly smaller than the effects during the placebo phase in all the tests (e.g., the Digit Symbol Substitution Test; p < 0.001). CONCLUSIONS: The observed substantial decrease in plasma concentrations and effects of midazolam most likely results from induction of CYP3A4 by rifampin in both the gut wall and the liver. Orally administered midazolam is ineffective during rifampin treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The use of analogue scales in rating subjective feelings
BOND, A., & LADER, M. (1974) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1974.tb02285.x · Cited by 1,972
Christopher Gorski, J., Hall, S. D., Jones, D. R., & VandenBranden, M. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90543-6 · Cited by 395
Ged, C., Rouillon, J., Pichard, L., Combalbert, J., Bressot, N., Bories, P., Michel, H., Beaune, P., & Maurel, P. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03516.x · Cited by 333
Cited by
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Self-citationBertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Update: Clinically Significant Cytochrome P‐450 Drug Interactions
Michalets, E. L. (1998) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03830.x · Cited by 597
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Metadata
- Authors
- Backman, J. T., Olkkola, K. T., & Neuvonen, P. J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1996-01
- Volume
- 59
- Issue
- 1
- Pages
- 7-13
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2114089215
- Cited by
- 242
- References
- 3
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rifampin drastically reduces plasma concentrations and effects of oral midazolam. https://app.cochat.ai/papers/10.1016/s0009-9236(96)90018-1
- The paper
- Backman, J. T., Olkkola, K. T., & Neuvonen, P. J. (1996). Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/s0009-9236(96)90018-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.